Oxford Biomedica (also known as OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors and other viral vector types. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB is headquartered in Oxford, UK. It has 14 GMP production suites with bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, US. OXB offers

OXB has unique experience in developing and manufacturing lentiviral vector, AAV and adenoviral vector with expert capabilities from plasmid design to commercial GMP manufacturing and fill finish. OXB was the first commercial supplier of LV for a CAR-T product in the world. OXB has taken more than 30 customers’ projects to IND.

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB also offers adenovirus and MVA vaccine production services and has process development capabilities and analytical methods accepted by regulatory authorities enabling the delivery of projects from pre clinical to commercial stages.

OXB has unique in-house analytical development capabilities to characterise vector and achieve rapid batch release, included automated assays and advanced mass spectroscopy.

Additionally, OXB offers regulatory authoring and reviewing support for IND/IPMD, BLA/MAA submissions.

– Therapeutic areas: Cell and gene therapy, Vaccines

– Based in: Strasbourg & Lyon (FRANCE), Massachussetts (US)

– Employees: 500+

– Created in: 1996